Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
前日終値
$118.69
−$0.78 · -0.65%
日中の時刻はETです。市場データは遅延する場合があります。
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
日中レンジ
現在 $118.69
52週レンジ
現在 $118.69
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
76
割安
センチメント
61
強気
リスク
30
中程度のリスク
モメンタム
52
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
日中レンジ
現在 $118.69
52週レンジ
現在 $118.69
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 13.34億 USD | 13.61億 USD | 13.09億 USD | 11.69億 USD | 9.93億 USD |
| 売上原価 | 5.9億 USD | 5.82億 USD | 5.97億 USD | 5.46億 USD | 4.62億 USD |
| 粗利益 | 7.44億 USD | 7.79億 USD | 7.12億 USD | 6.23億 USD | 5.31億 USD |
| 研究開発 | 5976.6万 USD | 6942.2万 USD | 6303.5万 USD | 5863.1万 USD | 5520.1万 USD |
| 販売・一般管理 | 4.42億 USD | 4.22億 USD | 4.21億 USD | 3.74億 USD | 3.32億 USD |
| 営業費用 | 5.02億 USD | 5.57億 USD | 5.47億 USD | 4.67億 USD | 4.5億 USD |
| 支払利息 | 2870.4万 USD | 974.6万 USD | 1301.8万 USD | 1463万 USD | 1712.1万 USD |
| 減価償却費と償却費 | 1.12億 USD | 1.16億 USD | 9721.5万 USD | 9330.7万 USD | 9774.7万 USD |
| 営業利益 | 2.41億 USD | 2.22億 USD | 1.65億 USD | 1.56億 USD | 8075万 USD |
| 純利益 | 9730.8万 USD | 1.68億 USD | 1.18億 USD | 1.15億 USD | 4337.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$130.8
上昇余地(10.20%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2012年12月3日 | 2:1 | — | — |
株式分割 | 1993年1月11日 | 2:1 | — | — |
発効済み 2012年12月3日
2:1
発効済み 1993年1月11日
2:1
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.49億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1.45億0.19%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB1.08億0.06%1853億 USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF5565.87万0.06%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO4798.81万0.35%139.17億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS4214.44万0.12%338.69億 USD0.31%$78.35+0.32%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY4038.35万0.16%258.17億 USD0.23%$669.87+0.54%
Vanguard Morningstar Small-Cap Value ETFVBR3422.27万0.05%682億 USD0.05%$234.43+0.22%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
Vanguard Morningstar Small-Cap Value ETFVBRAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。